Top virologist Dr Shahid Jameel says pausing the AstraZeneca trials of the Oxford vaccine is a "welcome step" and proves the efficacy of the trial process. On ICMR's release of a sero survey conducted in May, he says he doesn't see the usefulness of releasing the study findings after three months. Of the millions of Covid cases reported across the world, there have only been a handful of reinfection cases reported, so he doesn't see it as a big cause of concern.